• Gilead Sciences, Inc. recently announced that the FDA accepted its New Drug Application for an investigational once-daily single-tablet HIV regimen combining bictegravir 75 mg and lenacapavir 50 mg for virologically suppressed adults, granting priority review with a PDUFA action date of August 27, 2026, based on positive Phase 3 ARTISTRY-1 and ARTISTRY-2 data.
• The filing underscores Gilead’s efforts to refresh its core HIV portfolio with a compact regimen that maintained virological suppression, showed favorable tolerability, and improved patient-reported treatment satisfaction in an older study population without meaningful weight impact.
• We’ll now examine how this priority-reviewed bictegravir/lenacapavir HIV regimen could influence Gilead’s long-term growth narrative built around its HIV franchise.

AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Gilead Sciences Investment Narrative Recap

To own Gilead, you need to believe its HIV engine can keep driving the story while newer assets in prevention and oncology slowly broaden the base. The priority-reviewed bictegravir/lenacapavir pill reinforces that HIV remains the key near term catalyst, while policy and pricing pressure on US HIV treatment and prevention remains the biggest current risk. This filing looks additive to the narrative rather than changing it in a material way.

The most relevant recent development alongside this HIV filing is Gilead’s completion of the Arcellx acquisition, which brings full ownership of anito cel in multiple myeloma. Together, an investigational best in class HIV tablet and a new cell therapy highlight how Gilead is trying to balance its dependence on HIV with a growing oncology portfolio, creating multiple shots on goal for future approvals and helping offset eventual HIV patent cliffs.

Yet against this constructive setup, investors should be aware of how concentrated Gilead’s earnings still are in HIV and what happens if...

Gilead Sciences' narrative projects $33.6 billion revenue and $10.9 billion earnings by 2029. This requires 4.5% yearly revenue growth and about a $2.4 billion earnings increase from $8.5 billion today.

Uncover how Gilead Sciences' forecasts yield a $157.43 fair value, a 20% upside to its current price.

Exploring Other Perspectives

Some of the lowest estimate analysts were already assuming only about 2.4% annual revenue growth to roughly US$31.6 billion by 2029, so if you worry that HIV growth could stall while oncology uptake stays choppy, this latest HIV news might eventually soften that more pessimistic view or, if it disappoints, reinforce it.

Explore 6 other fair value estimates on Gilead Sciences - why the stock might be worth over 2x more than the current price!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Gilead Sciences research is our analysis highlighting 5 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Gilead Sciences research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Gilead Sciences' overall financial health at a glance.

Contemplating Other Strategies?

Our top stock finds are flying under the radar-for now. Get in early:

• Find 51 companies with promising cash flow potential yet trading below their fair value.
• Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• Outshine the giants: these 18 early-stage AI stocks could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.